SCHEMBL200831

SCHEMBL200831

Cc1cc(O)n(-c2ccccc2)n1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.63
CYP1A2 P05177 1/20 0.63
CYP2C19 P33261 1/20 0.63
FCGR1A P12314 1/20 0.61
NPC1 O15118 1/20 0.61
RAB9A P51151 1/20 0.61
NTRK1 P04629 1/20 0.57
GAA P10253 5/20 0.56
HPGD P15428 3/20 0.56
ALDH1A1 P00352 2/20 0.51
KDM4E B2RXH2 1/20 0.51
MAPT P10636 1/20 0.51
HSD17B10 Q99714 1/20 0.51
TSHR P16473 3/20 0.51
KCNJ6 P48051 1/20 0.51
KCNJ5 P48544 1/20 0.51
KCNJ3 P48549 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.49
KMT2A Q03164 1/20 0.48
LMNA P02545 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13292368 0.86 MAPK1 (0.58) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL28620570 0.86 MAPK1 (0.47) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL11441588 0.86 CYP1A2 (0.47) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL30490040 0.82 MAPT (0.47) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL10712366 0.82 CYP1A2 (0.53) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL23403503 0.82 ALDH1A1 (0.67) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL11436903 0.82 MAPK1 (0.44) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL10707004 0.82 POLB (0.60) MAPK1CYP1A2CYP2C19FCGR1ANPC1
SCHEMBL12467265 0.82 GAA (0.63) CYP1A2CYP2C19NPC1RAB9ANTRK1
SCHEMBL10780565 0.82 MAPK1 (0.61) MAPK1CYP1A2CYP2C19FCGR1ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 176 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113336704-B Danshensu derivative and preparation method and medical application thereof 上海大学 2022-10-11 CN claimed
CN-113336704-A Danshensu derivative and preparation method and medical application thereof 上海大学 2021-09-03 CN claimed
US-4816454-A CARDIOVASCULAR DISORDERS CASSELLA AKTIENGESELLSCHAFT (DE) 1989-03-28 US claimed
EP-0175363-A2 4,5-Dihydro-3(2H)-pyridazinones, process for their preparation and their use CASSELLA Aktiengesellschaft (DE) 1986-03-26 EP claimed
US-3945991-A Heterocyclic azo compounds containing a quaternated hydrazide group CIBA-GEIGY AG (CH) 1976-03-23 US claimed
CN-122029152-A Antioxidant drug conjugate FPR1 modulators, compositions comprising the modulators, and methods of use thereof 百放开曼有限公司 2026-05-12 CN disclosed
WO-2025118148-A1 ANTIOXIDANT DRUG-CONJUGATE MODULATORS OF FPR1, COMPOSITIONS COMPRISING THE MODULATOR, AND METHODS OF USING THE SAME BIOFRONT LTD (KY) 2025-06-12 WO disclosed
CN-119930520-A N-aryl pyrazole compound, and pharmaceutical composition and application thereof 中国药科大学 2025-05-06 CN disclosed
CN-113880805-B 4-Substituted quinoline derivative, preparation method and application thereof 东莞市东阳光农药研发有限公司 2025-01-10 CN disclosed
CN-119143824-A 3-Methyl-1-phenyl-1H-pyrazole-5-O-beta-D-glucoside and preparation method, pharmaceutical composition and application thereof 江苏万高药业股份有限公司 2024-12-17 CN disclosed
US-11912664-B2 Determining small molecule-protein and protein-protein interactions PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) 2024-02-27 US disclosed
CN-117069714-A Bis (pyrazolyl) methane derivative and application thereof 中国药科大学 2023-11-17 CN disclosed
EP-0185620-A2 Monoazo compounds CIBA-GEIGY AG (CH) 1986-06-25 EP disclosed
EP-0177710-A1 Phenyl urea derivatives BAYER AG (DE) 1986-04-16 EP disclosed
US-4517254-A ALKALI METAL HYDROXIDE, AMINOALKYLPOLYACID COMPOUNT SCHERING AKTIENGESELLSCHAFT (DE) 1985-05-14 US disclosed
EP-0139090-A1 Process for the pre-treatment of polyimides SCHERING AKTIENGESELLSCHAFT (DE) 1985-05-02 EP disclosed
US-4248632-A ACTIVATION OF A POLYMER SURFACE WITH A PALLADIUM COMPLEX SALT SCHERING AKTIENGESELLSCHAFT (DE) 1981-02-03 US disclosed
US-4217272-A DYEING CELLULOSIC FIBERS STERLING DRUG INC. (US) 1980-08-12 US disclosed
US-4153598-A Monoazo and diazo colorants from aminoalkylanilines and bis(aminoalkyl)anilines STERLING DRUG INC. (US) 1979-05-08 US disclosed
US-3945991-A Heterocyclic azo compounds containing a quaternated hydrazide group CIBA-GEIGY AG (CH) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912664-B2 Determining small molecule-protein and protein-protein interactions MAX, IK, CRYAA MAPK1 1809/4885CYP1A2 4117/4885CYP2C19 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.